APO Research
Talk to an analyst

APO RESEARCH · REPORT

Canine Arthritis Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Canine Arthritis Therapeutics Market Analysis and Forecast 2026-2032

2 January 2026194 pages

Choose your research edition.

Industry ResearchCanine Arthritis Therapeutics Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Canine Arthritis Therapeutics Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Canine Arthritis Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Canine Arthritis Therapeutics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Canine Arthritis Therapeutics Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Canine Arthritis Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Canine Arthritis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Canine Arthritis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Canine Arthritis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Canine Arthritis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Canine Arthritis Therapeutics include Zoetis Inc, VetStem Biopharma, Vetoquinol S.A., Norbrook Laboratories Limited, Elanco, Dechra Pharmaceuticals Plc, Boehringer Ingelheim and Aratana Therapeutics Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Canine Arthritis Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Canine Arthritis Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Canine Arthritis Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Canine Arthritis Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Canine Arthritis Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Canine Arthritis Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Canine Arthritis Therapeutics Segment by Company

Zoetis Inc

VetStem Biopharma

Vetoquinol S.A.

Norbrook Laboratories Limited

Elanco

Dechra Pharmaceuticals Plc

Boehringer Ingelheim

Aratana Therapeutics Inc

Canine Arthritis Therapeutics Segment by Type

Stem Cell Therapy

Non-Steroidal Anti-Inflammatory Drugs

Opioids

Canine Arthritis Therapeutics Segment by Application

Retail Pharmacies

Veterinary Hospitals and Clinics

Drug Stores

Canine Arthritis Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Canine Arthritis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Canine Arthritis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Canine Arthritis Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Canine Arthritis Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Canine Arthritis Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Canine Arthritis Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Canine Arthritis Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Stem Cell Therapy Major Player Table 3. Non-Steroidal Anti-Inflammatory Drugs Major Player Table 4. Opioids Major Player Table 5. Global Canine Arthritis Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Retail Pharmacies Major Player Table 7. Veterinary Hospitals and Clinics Major Player Table 8. Drug Stores Major Player Table 9. Canine Arthritis Therapeutics Industry Trends Table 10. Canine Arthritis Therapeutics Industry Drivers Table 11. Canine Arthritis Therapeutics Industry Opportunities and Challenges Table 12. Canine Arthritis Therapeutics Industry Restraints Table 13. Global Canine Arthritis Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Canine Arthritis Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Canine Arthritis Therapeutics Market Share by Region (2021-2026) Table 16. Global Canine Arthritis Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Canine Arthritis Therapeutics Market Share by Region (2027-2032) Table 18. Global Canine Arthritis Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Canine Arthritis Therapeutics Revenue Market Share by Players (2021-2026) Table 20. Global Canine Arthritis Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Canine Arthritis Therapeutics Key Players Headquarters & Area Served Table 22. Global Canine Arthritis Therapeutics Players, Product Type & Application Table 23. Global Canine Arthritis Therapeutics Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Canine Arthritis Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Canine Arthritis Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Canine Arthritis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Canine Arthritis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Canine Arthritis Therapeutics Revenue Market Share by Type (2021-2026) Table 30. Global Canine Arthritis Therapeutics Revenue Market Share by Type (2027-2032) Table 31. Global Canine Arthritis Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Canine Arthritis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Canine Arthritis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Canine Arthritis Therapeutics Revenue Market Share by Application (2021-2026) Table 35. Global Canine Arthritis Therapeutics Revenue Market Share by Application (2027-2032) Table 36. Zoetis Inc Company Information Table 37. Zoetis Inc Business Overview Table 38. Zoetis Inc Canine Arthritis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Zoetis Inc Canine Arthritis Therapeutics Product Portfolio Table 40. Zoetis Inc Recent Development Table 41. VetStem Biopharma Company Information Table 42. VetStem Biopharma Business Overview Table 43. VetStem Biopharma Canine Arthritis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. VetStem Biopharma Canine Arthritis Therapeutics Product Portfolio Table 45. VetStem Biopharma Recent Development Table 46. Vetoquinol S.A. Company Information Table 47. Vetoquinol S.A. Business Overview Table 48. Vetoquinol S.A. Canine Arthritis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Vetoquinol S.A. Canine Arthritis Therapeutics Product Portfolio Table 50. Vetoquinol S.A. Recent Development Table 51. Norbrook Laboratories Limited Company Information Table 52. Norbrook Laboratories Limited Business Overview Table 53. Norbrook Laboratories Limited Canine Arthritis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Norbrook Laboratories Limited Canine Arthritis Therapeutics Product Portfolio Table 55. Norbrook Laboratories Limited Recent Development Table 56. Elanco Company Information Table 57. Elanco Business Overview Table 58. Elanco Canine Arthritis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Elanco Canine Arthritis Therapeutics Product Portfolio Table 60. Elanco Recent Development Table 61. Dechra Pharmaceuticals Plc Company Information Table 62. Dechra Pharmaceuticals Plc Business Overview Table 63. Dechra Pharmaceuticals Plc Canine Arthritis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Dechra Pharmaceuticals Plc Canine Arthritis Therapeutics Product Portfolio Table 65. Dechra Pharmaceuticals Plc Recent Development Table 66. Boehringer Ingelheim Company Information Table 67. Boehringer Ingelheim Business Overview Table 68. Boehringer Ingelheim Canine Arthritis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Boehringer Ingelheim Canine Arthritis Therapeutics Product Portfolio Table 70. Boehringer Ingelheim Recent Development Table 71. Aratana Therapeutics Inc Company Information Table 72. Aratana Therapeutics Inc Business Overview Table 73. Aratana Therapeutics Inc Canine Arthritis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Aratana Therapeutics Inc Canine Arthritis Therapeutics Product Portfolio Table 75. Aratana Therapeutics Inc Recent Development Table 76. North America Canine Arthritis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 77. North America Canine Arthritis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 78. North America Canine Arthritis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 79. North America Canine Arthritis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 80. North America Canine Arthritis Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 81. North America Canine Arthritis Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 82. North America Canine Arthritis Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 83. Europe Canine Arthritis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 84. Europe Canine Arthritis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 85. Europe Canine Arthritis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 86. Europe Canine Arthritis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 87. Europe Canine Arthritis Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Europe Canine Arthritis Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 89. Europe Canine Arthritis Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 90. China Canine Arthritis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 91. China Canine Arthritis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 92. China Canine Arthritis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 93. China Canine Arthritis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 94. Asia Canine Arthritis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 95. Asia Canine Arthritis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 96. Asia Canine Arthritis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 97. Asia Canine Arthritis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 98. Asia Canine Arthritis Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Asia Canine Arthritis Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 100. Asia Canine Arthritis Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 101. SAMEA Canine Arthritis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 102. SAMEA Canine Arthritis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 103. SAMEA Canine Arthritis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 104. SAMEA Canine Arthritis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 105. SAMEA Canine Arthritis Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. SAMEA Canine Arthritis Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 107. SAMEA Canine Arthritis Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Canine Arthritis Therapeutics Image Figure 2. Global Canine Arthritis Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Canine Arthritis Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Stem Cell Therapy Image Figure 5. Non-Steroidal Anti-Inflammatory Drugs Image Figure 6. Opioids Image Figure 7. Global Canine Arthritis Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Canine Arthritis Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 9. Retail Pharmacies Image Figure 10. Veterinary Hospitals and Clinics Image Figure 11. Drug Stores Image Figure 12. Global Canine Arthritis Therapeutics Market Size (US$ Million) & (2021-2032) Figure 13. Global Canine Arthritis Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Canine Arthritis Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Canine Arthritis Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Canine Arthritis Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Canine Arthritis Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Canine Arthritis Therapeutics Revenue Market Share by Type (2021-2032) Figure 20. Global Canine Arthritis Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Canine Arthritis Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Canine Arthritis Therapeutics Revenue Market Share by Application (2021-2032) Figure 23. North America Canine Arthritis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Canine Arthritis Therapeutics Revenue Share by Type (2021-2032) Figure 25. North America Canine Arthritis Therapeutics Revenue Share by Application (2021-2032) Figure 26. North America Canine Arthritis Therapeutics Revenue Share by Country (2021-2032) Figure 27. United States Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Canine Arthritis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Canine Arthritis Therapeutics Revenue Share by Type (2021-2032) Figure 32. Europe Canine Arthritis Therapeutics Revenue Share by Application (2021-2032) Figure 33. Europe Canine Arthritis Therapeutics Revenue Share by Country (2021-2032) Figure 34. Germany Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Canine Arthritis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Canine Arthritis Therapeutics Revenue Share by Type (2021-2032) Figure 44. China Canine Arthritis Therapeutics Revenue Share by Application (2021-2032) Figure 45. Asia Canine Arthritis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Canine Arthritis Therapeutics Revenue Share by Type (2021-2032) Figure 47. Asia Canine Arthritis Therapeutics Revenue Share by Application (2021-2032) Figure 48. Asia Canine Arthritis Therapeutics Revenue Share by Region (2021-2032) Figure 49. Japan Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Canine Arthritis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Canine Arthritis Therapeutics Revenue Share by Type (2021-2032) Figure 57. SAMEA Canine Arthritis Therapeutics Revenue Share by Application (2021-2032) Figure 58. SAMEA Canine Arthritis Therapeutics Revenue Share by Country (2021-2032) Figure 59. Brazil Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Canine Arthritis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Stem Cell Therapy
  • Non-Steroidal Anti-Inflammatory Drugs
  • Opioids
Applications
  • Retail Pharmacies
  • Veterinary Hospitals and Clinics
  • Drug Stores
Companies covered
  • Zoetis Inc
  • VetStem Biopharma
  • Vetoquinol S.A.
  • Norbrook Laboratories Limited
  • Elanco
  • Dechra Pharmaceuticals Plc
  • Boehringer Ingelheim
  • Aratana Therapeutics Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Canine Arthritis Therapeutics Market by Type
  3. 1.2.1 Global Canine Arthritis Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Stem Cell Therapy
  5. 1.2.3 Non-Steroidal Anti-Inflammatory Drugs
  6. 1.2.4 Opioids
  7. 1.3 Canine Arthritis Therapeutics Market by Application
  8. 1.3.1 Global Canine Arthritis Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Retail Pharmacies
  10. 1.3.3 Veterinary Hospitals and Clinics
  11. 1.3.4 Drug Stores
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Canine Arthritis Therapeutics Market Dynamics
  1. 2.1 Canine Arthritis Therapeutics Industry Trends
  2. 2.2 Canine Arthritis Therapeutics Industry Drivers
  3. 2.3 Canine Arthritis Therapeutics Industry Opportunities and Challenges
  4. 2.4 Canine Arthritis Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Canine Arthritis Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Canine Arthritis Therapeutics Growth Trends by Region
  3. 3.2.1 Global Canine Arthritis Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Canine Arthritis Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Canine Arthritis Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Canine Arthritis Therapeutics Revenue by Players
  2. 4.1.1 Global Canine Arthritis Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Canine Arthritis Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Canine Arthritis Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Canine Arthritis Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Canine Arthritis Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Canine Arthritis Therapeutics Players, Product Type & Application
  8. 4.5 Global Canine Arthritis Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Canine Arthritis Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Canine Arthritis Therapeutics Tier 1, Tier 2, and Tier 3
5 Canine Arthritis Therapeutics Market Size by Type
  1. 5.1 Global Canine Arthritis Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Canine Arthritis Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Canine Arthritis Therapeutics Revenue Market Share by Type (2021-2032)
6 Canine Arthritis Therapeutics Market Size by Application
  1. 6.1 Global Canine Arthritis Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Canine Arthritis Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Canine Arthritis Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Zoetis Inc
  2. 7.1.1 Zoetis Inc Company Information
  3. 7.1.2 Zoetis Inc Business Overview
  4. 7.1.3 Zoetis Inc Canine Arthritis Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Zoetis Inc Canine Arthritis Therapeutics Product Portfolio
  6. 7.1.5 Zoetis Inc Recent Developments
  7. 7.2 VetStem Biopharma
  8. 7.2.1 VetStem Biopharma Company Information
  9. 7.2.2 VetStem Biopharma Business Overview
  10. 7.2.3 VetStem Biopharma Canine Arthritis Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 VetStem Biopharma Canine Arthritis Therapeutics Product Portfolio
  12. 7.2.5 VetStem Biopharma Recent Developments
  13. 7.3 Vetoquinol S.A.
  14. 7.3.1 Vetoquinol S.A. Company Information
  15. 7.3.2 Vetoquinol S.A. Business Overview
  16. 7.3.3 Vetoquinol S.A. Canine Arthritis Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Vetoquinol S.A. Canine Arthritis Therapeutics Product Portfolio
  18. 7.3.5 Vetoquinol S.A. Recent Developments
  19. 7.4 Norbrook Laboratories Limited
  20. 7.4.1 Norbrook Laboratories Limited Company Information
  21. 7.4.2 Norbrook Laboratories Limited Business Overview
  22. 7.4.3 Norbrook Laboratories Limited Canine Arthritis Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Norbrook Laboratories Limited Canine Arthritis Therapeutics Product Portfolio
  24. 7.4.5 Norbrook Laboratories Limited Recent Developments
  25. 7.5 Elanco
  26. 7.5.1 Elanco Company Information
  27. 7.5.2 Elanco Business Overview
  28. 7.5.3 Elanco Canine Arthritis Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Elanco Canine Arthritis Therapeutics Product Portfolio
  30. 7.5.5 Elanco Recent Developments
  31. 7.6 Dechra Pharmaceuticals Plc
  32. 7.6.1 Dechra Pharmaceuticals Plc Company Information
  33. 7.6.2 Dechra Pharmaceuticals Plc Business Overview
  34. 7.6.3 Dechra Pharmaceuticals Plc Canine Arthritis Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Dechra Pharmaceuticals Plc Canine Arthritis Therapeutics Product Portfolio
  36. 7.6.5 Dechra Pharmaceuticals Plc Recent Developments
  37. 7.7 Boehringer Ingelheim
  38. 7.7.1 Boehringer Ingelheim Company Information
  39. 7.7.2 Boehringer Ingelheim Business Overview
  40. 7.7.3 Boehringer Ingelheim Canine Arthritis Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Boehringer Ingelheim Canine Arthritis Therapeutics Product Portfolio
  42. 7.7.5 Boehringer Ingelheim Recent Developments
  43. 7.8 Aratana Therapeutics Inc
  44. 7.8.1 Aratana Therapeutics Inc Company Information
  45. 7.8.2 Aratana Therapeutics Inc Business Overview
  46. 7.8.3 Aratana Therapeutics Inc Canine Arthritis Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Aratana Therapeutics Inc Canine Arthritis Therapeutics Product Portfolio
  48. 7.8.5 Aratana Therapeutics Inc Recent Developments
8 North America
  1. 8.1 North America Canine Arthritis Therapeutics Revenue (2021-2032)
  2. 8.2 North America Canine Arthritis Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Canine Arthritis Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Canine Arthritis Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Canine Arthritis Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Canine Arthritis Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Canine Arthritis Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Canine Arthritis Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Canine Arthritis Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Canine Arthritis Therapeutics Revenue by Country
  11. 8.6.1 North America Canine Arthritis Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Canine Arthritis Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Canine Arthritis Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Canine Arthritis Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Canine Arthritis Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Canine Arthritis Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Canine Arthritis Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Canine Arthritis Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Canine Arthritis Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Canine Arthritis Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Canine Arthritis Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Canine Arthritis Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Canine Arthritis Therapeutics Revenue by Country
  11. 9.6.1 Europe Canine Arthritis Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Canine Arthritis Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Canine Arthritis Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Canine Arthritis Therapeutics Revenue (2021-2032)
  2. 10.2 China Canine Arthritis Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Canine Arthritis Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Canine Arthritis Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Canine Arthritis Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Canine Arthritis Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Canine Arthritis Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Canine Arthritis Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Canine Arthritis Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Canine Arthritis Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Canine Arthritis Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Canine Arthritis Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Canine Arthritis Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Canine Arthritis Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Canine Arthritis Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Canine Arthritis Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Canine Arthritis Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Canine Arthritis Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Canine Arthritis Therapeutics Revenue by Country
  11. 11.6.1 Asia Canine Arthritis Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Canine Arthritis Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Canine Arthritis Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Canine Arthritis Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Canine Arthritis Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Canine Arthritis Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Canine Arthritis Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Canine Arthritis Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Canine Arthritis Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Canine Arthritis Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Canine Arthritis Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Canine Arthritis Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Canine Arthritis Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Canine Arthritis Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Canine Arthritis Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Canine Arthritis Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst